Skip to main content

International Journal of Pharmaceutics

  • ISSN: 0378-5173

Editor-In-Chief: Siepmann

Next planned ship date: May 27, 2024

  • 5 Year impact factor: 5.8
  • Impact factor: 5.8

The International Journal of Pharmaceutics has an open access companion journal International… Read more

Subscription options

Next planned ship date:
May 27, 2024

Institutional subscription on ScienceDirect

Request a sales quote
The International Journal of Pharmaceutics has an open access companion journal International Journal of Pharmaceutics: X which has the same aims and scope and peer-review process. To submit to International Journal of Pharmaceutics: X visit https://www.editorialmanager.com/IJPHARMX/default.aspx.

The International Journal of Pharmaceutics is the third most cited journal in the "Pharmacy & Pharmacology" category out of 366 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.

Editorial Policy
The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.

Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.